Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Share-based Compensation (2016 - 2025)

ImmunityBio (IBRX) has disclosed Share-based Compensation for 13 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 3.23% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.8 million through Dec 2025, up 6.9% year-over-year, with the annual reading at $36.8 million for FY2025, 6.9% up from the prior year.
  • Share-based Compensation for Q4 2025 was $8.7 million at ImmunityBio, down from $8.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $17.9 million in Q2 2021, with the low at $7.5 million in Q3 2024.
  • Average Share-based Compensation over 5 years is $10.9 million, with a median of $10.1 million recorded in 2022.
  • The sharpest move saw Share-based Compensation surged 5447.52% in 2021, then crashed 48.17% in 2024.
  • Over 5 years, Share-based Compensation stood at $10.2 million in 2021, then decreased by 8.15% to $9.4 million in 2022, then soared by 36.62% to $12.8 million in 2023, then fell by 29.25% to $9.0 million in 2024, then decreased by 3.23% to $8.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $8.7 million, $8.9 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.